Related Experiment Video
Updated: Jan 17, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Overview of the tuberculosis vaccine development landscape
1ICMR-National Institute for Research in Tuberculosis, Chetpet, Chennai, India.
Abstract:
The introduction of a novel tuberculosis (TB) vaccine will help to decrease TB incidence and is essential for achieving TB elimination. Given the limitations of BCG, there is a requirement for new vaccines for TB that can prevent the development of TB disease across all age groups. Currently, there are about 17 vaccines in clinical development from phase I to phase III. They belong to different vaccine types namely - viral vector, mycobacterial inactivated, mycobacterial live attenuated, protein subunit and mRNA vaccines. The TB vaccines in development are intended to prevent infection or disease, prevent recurrence or to act as therapeutic vaccines. Revaccination with BCG vaccine is also currently being evaluated in the prevention of TB. Developing an effective TB vaccine is challenging. Basic science research, advancing clinical development and research to ensure public health impact is crucial in TB vaccine development. Engaging stakeholders, securing funding, and advocating for support could expedite the development of new TB vaccines.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Microorganisms in Medicine and Therapeutics

